Loading...

Brilliant Violet 785™ anti-mouse CD11c Antibody

Pricing & Availability
Clone
N418 (See other available formats)
Regulatory Status
RUO
Other Names
αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
N418_BV785_061812
C57BL/6 mouse splenocytes were stained with I-A/I-E FITC and CD11c (clone N418) Brilliant Violet 785™.
  • N418_BV785_061812
    C57BL/6 mouse splenocytes were stained with I-A/I-E FITC and CD11c (clone N418) Brilliant Violet 785™.
See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
117335 125 µL 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
117336 50 µg 229€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse spleen dendritic cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation3, immunohistochemical staining of acetone-fixed frozen sections3, immunofluorescence microscopy5, 9 (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections10), and spatial biology (IBEX)22,23.

Application References

(PubMed link indicates BioLegend citation)
  1. Granucci F, et al. 1997. J. Immunol. 159:1794.
  2. Stokes RW, et al. 1998. J. Immunol. 160:5514.
  3. Metlay JP, et al. 1990. J. Exp. Med. 171:1753. (IHC, IP)
  4. Ma XT, et al. 2006. Cancer Research 66:1169.
  5. Chin RK, et al. 2006. J. Immunol. 177:290. (IF)
  6. Cervantes-Barragan L, et al. 2007. Blood 109:1131. (FC) PubMed
  7. Turnquist HR, et al. 2007. J. Immunol. 178:7018. (FC) PubMed
  8. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  9. You Y, et al. 2009. J. Immunol. 182:7343. (IF) PubMed
  10. Roland CL, et al. 2009. Mol. Cancer Res. 8:1761. (IHC, FC) PubMed
  11. Wikstrom M, et al.2006. J. Immunol. 177:913. PubMed
  12. Pericolini E, et al. 2008. J. Leukocyte Biol. 83:1286. PubMed
  13. Randall LM, et al. 2008. Infect. Immun.76:3312. PubMed
  14. Fahlen-Yrild L, et al. 2009. J. Immunol. 183:5032. PubMed
  15. Osterholzer JJ, et al. 2009. J. Immunol. 183:8044. PubMed
  16. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  17. Eisenach PA, et al. 2010. J Cell Sci. 123:4182. PubMed
  18. Leppin K, et al. 2014. Invest. Ophthalmol. Vis. Sci. 55:3603. PubMed
  19. Sakai F, et al. 2014. PLoS One. 9:105370. PubMed
  20. Gibbins JD, et al. 2014. Blood. 124:2953. PubMed
  21. White CE, et al. 2015. J Immunol. 194:697. PubMed
  22. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  23. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  24. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Watanabe K, et al. 2018. JCI Insight. 3. PubMed
  2. Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed
  3. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  4. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  5. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  6. Brown SM et al. 2017. Endocrinology. 158(10):3592-3604 . PubMed
  7. Han SJ et al. 2017. Immunity. 47(6):1154-1168 . PubMed
  8. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  9. Petkevicius K, et al. 2019. Elife. 8:e47990. PubMed
  10. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  11. Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed
  12. Ji DX, et al. 2019. Nat Microbiol. 1.644444444. PubMed
  13. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  14. McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed
  15. Hays C, et al. 2020. eLife. 8:e48772.. PubMed
  16. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  17. Casadesús AV, et al. 2020. Oncoimmunology. 9:1770565. PubMed
  18. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  19. AM C, et al. 2015. Proc Natl Acad Sci U S A. 112 7557 . PubMed
  20. E O’Koren, R Mathew, D Saban 2016. Sci Rep. 6:20636. PubMed
  21. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  22. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  23. Devos M, et al. 2020. J Exp Med. 217:00:00. PubMed
  24. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  25. Liu X, et al. 2020. Cell Host Microbe. 28(5):683-698.e6. PubMed
  26. Nascimento DC, et al. 2021. Immunity. :. PubMed
  27. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  28. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  29. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  30. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  31. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  32. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  33. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  34. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  35. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  36. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  37. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  38. Gilbert NM, et al. 2021. Biol Open. 10:. PubMed
  39. Wu X, et al. 2021. Elife. 10:. PubMed
  40. Schepanski S, et al. 2022. Nat Commun. 13:4571. PubMed
  41. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  42. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  43. Draijer C, et al. 2023. Front Immunol. 13:1056477. PubMed
  44. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  45. Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed
  46. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  47. An HS, et al. 2023. Int J Biol Sci. 19:1163. PubMed
  48. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
RRID
AB_11219204 (BioLegend Cat. No. 117335)
AB_2565268 (BioLegend Cat. No. 117336)

Antigen Details

Structure
Integrin α-chain, associates with integrin β2 (CD18), 150 kD
Distribution

Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells

Function
Cellular adhesion
Ligand/Receptor
iC3b, fibrinogen
Cell Type
Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen Facts Book Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Lopez-Rodriguez C, et al. 1996. J. Immunol. 156:3780.

Gene ID
16411 View all products for this Gene ID
UniProt
View information about CD11c on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account